Dr. Mathieu Lupien is a Senior Scientist at the Princess Margaret Cancer Centre, a Professor at the University of Toronto and holds a cross-appointment with the Ontario Institute for Cancer Research. He is a Research Executive and Research Council on Oncology member at the Princess Margaret Cancer Centre.Dr. Lupien’s research demonstrates that cancer is a disease of the chromatin. Amongst key discoveries, Dr. Lupien’s research revealed a new type of genomic variation, known as chromatin variants, to pioneer the identification of cancer drivers in the non-coding cancer genome. His work also showed that cancer-specific chromatin variants could support oncogenesis independently of genetic variants (mutations). Finally, Dr. Lupien’s research demonstrated the efficacy of epigenetic therapy that targets chromatin variants to block cancer development and progression. Among other honours, Dr. Lupien is a recipient of the Allan Slaight Collaborator Award, the Mona Gauthier Award, the Canadian Cancer Society Bernard and Francine Dorval Award for Excellence, a three-time recipient of the Investigator Award from the Ontario Institute for Cancer Research, a two times recipient of the Till and McCulloch Discovery of the Year award and co-founder of CoBE.Dr. Lupien earned his PhD in experimental medicine at McGill University under the leadership of Dr. Sylvie Mader and carried out postdoctoral training in medical oncology as an Era of Hope Fellow at the Dana-Farber Cancer Institute/Harvard Medical School under the mentorship of Dr. Myles Brown followed by a PLDA at Harvard Business School. Dr. Lupien joined the Princess Margaret Cancer Centre and the University of Toronto in 2012.